{"id":"https://openalex.org/W2099516828","doi":"https://doi.org/10.1158/1535-7163.targ-09-a71","title":"Abstract A71: Basal- and treatment-induced activation of the PI3K-AKT pathway are critical determinants of the efficacy of the MEK inhibitor AZD6244 (ARRY-142886) in melanoma","display_name":"Abstract A71: Basal- and treatment-induced activation of the PI3K-AKT pathway are critical determinants of the efficacy of the MEK inhibitor AZD6244 (ARRY-142886) in melanoma","publication_year":2009,"publication_date":"2009-12-01","ids":{"openalex":"https://openalex.org/W2099516828","doi":"https://doi.org/10.1158/1535-7163.targ-09-a71","mag":"2099516828"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.targ-09-a71","doi":"https://doi.org/10.1158/1535-7163.targ-09-a71","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.targ-09-a71","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5044747566","display_name":"Vashisht Gopal Yennu Nanda","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Vashisht G. Yennu-Nanda","raw_affiliation_strings":["1 UT M. D. Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1 UT M. D. Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112904352","display_name":"Wanleng Deng","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Wanleng Deng","raw_affiliation_strings":["1 UT M. D. Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1 UT M. D. Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039299082","display_name":"Paul D. Smith","orcid":"https://orcid.org/0000-0002-2812-5978","observed_orcids":["https://orcid.org/0000-0002-2812-5978"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Paul D. Smith","raw_affiliation_strings":["2 AstraZeneca, Macclesfield, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2 AstraZeneca, Macclesfield, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5048327749","display_name":"Michael A. Davies","orcid":"https://orcid.org/0000-0002-0977-0912","observed_orcids":["https://orcid.org/0000-0002-0977-0912"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael A. Davies","raw_affiliation_strings":["1 UT M. D. Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1 UT M. D. Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"8","issue":"12_Supplement","first_page":"A71","last_page":"A71"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10169","display_name":"Protein Kinase Regulation and GTPase Signaling","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12104","display_name":"Protein Tyrosine Phosphatases","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/selumetinib","display_name":"selumetinib","score":0.8949999809265137},{"id":"https://openalex.org/keywords/mek-inhibitors","display_name":"MEK inhibitors","score":0.875},{"id":"https://openalex.org/keywords/pi3k-akt-signaling","display_name":"PI3K/Akt signaling","score":0.8880000114440918},{"id":"https://openalex.org/keywords/braf-mutation","display_name":"BRAF mutation","score":0.8949999809265137},{"id":"https://openalex.org/keywords/nras-mutation","display_name":"NRAS mutation","score":0.7900000214576721},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.949999988079071},{"id":"https://openalex.org/keywords/akt-activation","display_name":"Akt activation","score":0.8519999980926514},{"id":"https://openalex.org/keywords/pten","display_name":"PTEN","score":0.7910000085830688},{"id":"https://openalex.org/keywords/mapk-signaling","display_name":"MAPK signaling","score":0.6039999723434448},{"id":"https://openalex.org/keywords/reverse-phase-protein-array","display_name":"reverse phase protein array","score":0.6930000185966492},{"id":"https://openalex.org/keywords/melanoma-cell-lines","display_name":"melanoma cell lines","score":0.7540000081062317},{"id":"https://openalex.org/keywords/patient-selection","display_name":"patient selection","score":0.5630000233650208},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.8360000252723694}],"concepts":[{"id":"https://openalex.org/C57074206","wikidata":"https://www.wikidata.org/wiki/Q14197552","display_name":"MAPK/ERK pathway","level":3,"score":0.7073472738265991},{"id":"https://openalex.org/C86554907","wikidata":"https://www.wikidata.org/wiki/Q285613","display_name":"PI3K/AKT/mTOR pathway","level":3,"score":0.6696513891220093},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6536661982536316},{"id":"https://openalex.org/C21790070","wikidata":"https://www.wikidata.org/wiki/Q18030215","display_name":"Neuroblastoma RAS viral oncogene homolog","level":5,"score":0.6441319584846497},{"id":"https://openalex.org/C75217442","wikidata":"https://www.wikidata.org/wiki/Q423650","display_name":"Protein kinase B","level":3,"score":0.6138102412223816},{"id":"https://openalex.org/C2781249067","wikidata":"https://www.wikidata.org/wiki/Q17142288","display_name":"MEK inhibitor","level":4,"score":0.537768542766571},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.5307564735412598},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.5225398540496826},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.45976489782333374},{"id":"https://openalex.org/C62112901","wikidata":"https://www.wikidata.org/wiki/Q189159","display_name":"Cell growth","level":2,"score":0.41946983337402344},{"id":"https://openalex.org/C81885089","wikidata":"https://www.wikidata.org/wiki/Q189082","display_name":"Cell culture","level":2,"score":0.4158942401409149},{"id":"https://openalex.org/C501734568","wikidata":"https://www.wikidata.org/wiki/Q42918","display_name":"Mutation","level":3,"score":0.3408544957637787},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.32775527238845825},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.3172624707221985},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.09115868806838989},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.08124294877052307},{"id":"https://openalex.org/C2781187634","wikidata":"https://www.wikidata.org/wiki/Q20969980","display_name":"KRAS","level":4,"score":0.05871999263763428},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1535-7163.targ-09-a71","doi":"https://doi.org/10.1158/1535-7163.targ-09-a71","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.targ-09-a71","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9476000070571899,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2007867839","https://openalex.org/W2055288483","https://openalex.org/W1649308583","https://openalex.org/W2022538402","https://openalex.org/W1963713713","https://openalex.org/W2124301770","https://openalex.org/W1991708036","https://openalex.org/W2497243288","https://openalex.org/W2090183017","https://openalex.org/W2548627249"],"abstract_inverted_index":{"Abstract":[0],"Over":[1],"80%":[2],"of":[3,9,18,41,62,69,83,118,128,148,160,179,198,210,231,242,269,287,314,340,372,385,402,414],"cutaneous":[4],"melanomas":[5],"have":[6],"constitutive":[7],"activation":[8,159,197,209,413],"the":[10,60,158,164,188,199,211,237,252,281,293,330,336,355,362,369,378,415],"RAS-RAF-MEK-MAPK":[11,64],"signaling":[12,161,182,201,375],"pathway,":[13],"which":[14,34],"is":[15,28],"a":[16,29,70,115,123,139,382],"result":[17],"activating":[19],"mutations":[20],"in":[21,47,51,131,163,187,247,275,284,292,309,325,329,347,354,361,388,408],"BRAF":[22,55,149],"(>60%)":[23],"or":[24,342],"NRAS":[25,151],"(\u223c20%).":[26],"AZD6244":[27,121,243,273,322,353,407],"highly":[30],"selective":[31],"MEK1/2":[32],"inhibitor,":[33],"was":[35],"well":[36],"tolerated,":[37],"induced":[38],"marked":[39],"reduction":[40],"tumor":[42],"P-MAPK":[43],"expression":[44,186,311,387],"and":[45,66,94,125,150,203,239,250,266,396,404],"resulted":[46,283,324,346],"\u223c15%":[48],"clinical":[49,67],"responses":[50],"melanoma":[52,104,390],"patients":[53],"with":[54,208,228,272,352,406],"mutations.":[56],"The":[57,145],"discordance":[58],"between":[59,196,374],"prevalence":[61],"activated":[63],"pathway":[65,72,202,213],"efficacy":[68,379],"potent":[71,265],"inhibitor":[73],"suggests":[74],"that":[75,321,410],"other":[76],"pathways":[77,85,162,376],"may":[78,86],"determine":[79],"efficacy.":[80],"Improved":[81],"understanding":[82],"such":[84],"lead":[87],"to":[88,193,215,254,301,377],"improved":[89],"patient":[90],"selection":[91],"for":[92,107,173,399],"AZD6244,":[93,380],"rational":[95],"combinatorial":[96],"approaches.":[97],"We":[98,156],"tested":[99],"17":[100],"molecularly":[101],"characterized":[102,157,236],"human":[103],"cell":[105,129,133,141,190,224,258,278,295,298,349,357,364,391],"lines":[106,113,137,191,225,259,299,392],"growth":[108,119],"inhibition":[109,268,401],"by":[110,166,344],"AZD6244.":[111],"Cell":[112],"demonstrated":[114],"wide":[116],"spectrum":[117],"inhibition;":[120],"produced":[122],"dose-":[124],"time-dependent":[126],"induction":[127,351,384],"death":[130,350],"sensitive":[132,256,297,331,363,389],"lines,":[134,358],"while":[135],"resistant":[136,222,294,337,356],"showed":[138,264,306],"G1":[140],"cycle":[142],"arrest":[143],"only.":[144],"mutational":[146],"status":[147],"did":[152],"not":[153,335,360],"predict":[154],"sensitivity.":[155,204],"cells":[165,207,409],"reverse":[167],"phase":[168],"protein":[169,185,245],"array":[170],"(RPPA)":[171],"analysis":[172,263],">100":[174],"proteins,":[175],"including":[176],"activation-specific":[177],"markers":[178],"multiple":[180],"critical":[181,370],"pathways.":[183],"Baseline":[184],"BRAF-mutant":[189,206,223,257],"failed":[192,300],"show":[194,216],"correlation":[195],"MAPK":[200],"Whilst":[205],"PI3K-AKT":[212],"tended":[214],"increased":[217,285,326],"resistance,":[218],"we":[219,235],"identified":[220],"two":[221,255],"(SKMEL5,":[226],"MEL624)":[227],"normal":[229],"levels":[230,286],"p-AKT.":[232],"Using":[233],"RPPA,":[234],"time-":[238],"dose-dependent":[240],"effects":[241],"on":[244],"networks":[246],"these":[248],"cells,":[249,333],"compared":[251],"results":[253],"(WM35,":[260],"A375).":[261],"RPPA":[262],"durable":[267],"MEK":[270,394],"activity":[271],"treatment":[274,282,323],"all":[276],"4":[277],"lines.":[279,365],"However,":[280],"p-AKT":[288],"after":[289],"24\u201348":[290],"hours":[291],"lines;":[296],"activate":[302],"AKT":[303,315,341,403],"but":[304,334,359],"instead":[305],"an":[307],"increase":[308],"PTEN":[310,327,386],"(negative":[312],"regulator":[313],"activation).":[316],"Parallel":[317],"transcriptional":[318],"profiling":[319],"revealed":[320],"mRNA":[328],"WM35":[332],"SKMEL5.":[338],"Inhibition":[339],"IGF1R":[343,405],"siRNA":[345],"synergistic":[348],"These":[366],"studies":[367],"support":[368],"nature":[371],"cross-talk":[373],"demonstrate":[381,397],"novel":[383],"following":[393],"inhibition,":[395],"synergy":[398],"combined":[400],"exhibit":[411],"treatment-induced":[412],"PI3K":[416],"pathway.":[417],"Citation":[418],"Information:":[419],"Mol":[420],"Cancer":[421],"Ther":[422],"2009;8(12":[423],"Suppl):A71.":[424]},"counts_by_year":[],"updated_date":"2026-10-17T09:40:24.721904","created_date":"2016-06-24T00:00:00"}